All 1 tracked stories fall under one category: acquisition. TwinStrand Biosciences is most often covered alongside DuplexSeq, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention TwinStrand Biosciences, all published on February 26, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about TwinStrand Biosciences
All 1 tracked stories fall under one category: acquisition. TwinStrand Biosciences is most often covered alongside DuplexSeq, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Biotech story that mention TwinStrand Biosciences, all published on February 26, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering TwinStrand Biosciences. Shared-story counts are live from our verified record — not editorial picks.
Scantox has acquired the DuplexSeq™ nonclinical genomics safety business from TwinStrand Biosciences, integrating ultra-sensitive sequencing technology into its pre-clinical service suite. This strategic move positions Scantox as a leader in high-resolution genetic toxicology, offering pharmaceutical clients unprecedented accuracy in identifying mutagenic risks.
TwinStrand Biosciences is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source
link? Report a data issue.